Semantic Scholar
Open Access
2020
88 sitasi
Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
Z. Ying
Haiyan Yang
Ye Guo
Wenyu Li
D. Zou
+11 lainnya
Abstrak
Despite numerous chimeric antigen receptor T‐cell (CAR‐T) trials conducted in China, no CAR‐T has been registered in the country. Furthermore, China law and regulations restrict the export of patient material for CAR‐T manufacture abroad. Relma‐cel (JWCAR029), an anti‐CD19 product produced with a commercial‐ready process in China, was evaluated in the first prospective, single‐arm, multicenter, pivotal study of CAR‐T therapy conducted under Chinese IND to support an NMPA‐accepted BLA submission in relapsed/refractory (r/r) LBCL (NCT04089215).
Topik & Kata Kunci
Penulis (16)
Z
Z. Ying
H
Haiyan Yang
Y
Ye Guo
W
Wenyu Li
D
D. Zou
D
Dao-bin Zhou
Z
Zhao Wang
M
Mingzhi Zhang
J
Jianqiu Wu
H
Hui Liu
P
Pian Zhang
S
Su Yang
Z
Zisong Zhou
H
Hongxia Zheng
Y
Yuqin Song
J
Jun Zhu
Akses Cepat
Informasi Jurnal
- Tahun Terbit
- 2020
- Bahasa
- en
- Total Sitasi
- 88×
- Sumber Database
- Semantic Scholar
- DOI
- 10.1002/cam4.3686
- Akses
- Open Access ✓